Docket #: S22-019
Single Molecule Sequencing and Methylation Profiling of Cell-Free DNA
Stanford inventors have developed a novel cancer detection assay that relies on sequencing single DNA molecules.
Existing methods of detecting cancer involve measuring the circulating tumor DNA (ctDNA) in patient blood. ctDNA measurement requires the addition of enzymes and other chemicals which cause oxidative damage to DNA and reduce the fidelity of sequences in the PCR amplification process. Stanford scientists have overcome these challenges by developing a DNA assay to detect and quantify ctDNA directly using single molecule sequencing. While next generation sequencing methods target methylated compounds, single molecule sequencing allows for direct detection and quantification of DNA originating from malignant cancer tumors. This assay offers a new framework of detection of cancer and other diseases without obtrusive pre-treatment of ctDNA.
Stage of Development
Proof of concept – in vitro data
Applications
- Cancer diagnostics
- Other disease diagnostics
Advantages
- Simpler than conventional methods
- Higher sensitivity to low-abundance reads
- Eliminates need for enzyme and other chemical additions
- Eliminates amplification bias that is common in conventional methods
Related Links
Patents
- Published Application: WO2023235379
Similar Technologies
-
Low-cost, Comprehensive Methylation Profiling Using Low DNA Inputs for Cancer Diagnostics S23-456Low-cost, Comprehensive Methylation Profiling Using Low DNA Inputs for Cancer Diagnostics
-
Quantitative AML patient risk assessment using RNA signatures associated with sensitivity and resistance to immune cell killing S23-017Quantitative AML patient risk assessment using RNA signatures associated with sensitivity and resistance to immune cell killing
-
Liquid Biopsies Using Cell-free RNA for Non-invasive Cancer Detection and Characterization S23-116Liquid Biopsies Using Cell-free RNA for Non-invasive Cancer Detection and Characterization